Revolutionizing dry eye management: Insights on perfluorohexyloctane from TFOS meeting

News
Video

Dr. Shane Kannarr discusses findings on perfluorohexyloctane at the Tear Film and Ocular Surface conference, highlighting its rapid symptom relief and enhanced patient satisfaction.

In a recent interview with Shane Kannarr, OD, at the Tear Film and Ocular Surface (TFOS) Basic Science and Clinical Relevance meeting in Venice, Italy, key insights were shared about his poster on early symptom relief and patient satisfaction with perfluorohexyloctane (PFHO) for treating dry eye disease. Kannarr emphasized the multifactorial nature of dry eye and the challenges practitioners face in retaining patient adherence to treatment regimens. Notably, PFHO has demonstrated significant efficacy, with symptom relief reported as early as three days after initiation of therapy.

Patient satisfaction was quantitatively assessed using a visual analog scale, where participants ranked their most troublesome symptoms. Remarkably, a 40% reduction in the most bothersome symptom was observed within three days. The top three symptoms identified by patients included dryness, blurred vision, and eye irritation, reflecting common concerns in dry eye management.

Kannarr highlighted the unique attributes of PFHO, which is a preservative-free, water-free topical solution that forms a protective monolayer to reduce tear film evaporation. This innovative approach not only provides rapid symptom relief but also demonstrates continued improvement over two weeks, with significant reductions in overall dry eye awareness and vision fluctuations.

He discussed patient demographics that may benefit most from PFHO, particularly those requiring immediate relief and those who have struggled with ongoing dry eye symptoms despite previous treatments. This new therapeutic option may enhance the treatment landscape for individuals who have not found success with standard therapies.

In summary, Kannarr’s insights underscore the importance of addressing both the clinical signs and symptomatic relief of dry eye disease, advocating for PFHO as a promising option for improving patient satisfaction and outcomes. This novel approach may transform how optometrists manage dry eye, providing patients with quicker, more effective relief.

Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.